Pilot study for T-cell lymphoma finds adding epigenetic drug to standard chemotherapy is effective

Nearly 90% of patients with an aggressive subtype of non-Hodgkin lymphoma had their cancer go into remission in a small phase 2 clinical trial testing a treatment aimed at making chemotherapy more effective, according to Weill Cornell Medicine and NewYork-Presbyterian investigators.

Leave A Comment

Your email address will not be published. Required fields are marked *